Arkolith/Insider Trading/RVNC/Form 4

Foley Mark J

CEO, DirectorRevance Therapeutics, Inc. (RVNC) · full profile →Form 4 · filed Jul 5, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$655K
Net Open-Market Flow
-$655K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 3, 2023Sell(S)26K$24.94$655K867K
Jun 30, 2023Grant(A)1K$15.61$16K893K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001479290-23-000081) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML